Low dose CP-690,550 (tofacitinib), a pan-JAK inhibitor, accelerates the onset of experimental autoimmune encephalomyelitis by potentiating Th17 differentiation

Biochemical and Biophysical Research Communications

Volumn 418, Issue 2, 2012, Pages 234-240

  Yoshida, Hideyuki ^a,b   Kimura, Akihiro ^a,b   Fukaya, Tomohiro ^a,b   Sekiya, Takashi ^a,b   Morita, Rimpei ^a,b   Shichita, Takashi ^a,b   Inoue, Hiromasa ^c   Yoshimura, Akihiko ^a,b  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Cytokine signaling; EAE; Helper T cells; Mouse

Indexed keywords

INTERFERON; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; STAT1 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; STAT6 PROTEIN; TOFACITINIB;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; CELL STRAIN HEK293; COLLAGEN INDUCED ARTHRITIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; IMMUNIZATION; IN VITRO STUDY; LYMPHOCYTE DIFFERENTIATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TH1 CELL; TH17 CELL; TH2 CELL;

ANIMALS; CELL DIFFERENTIATION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HEK293 CELLS; HUMANS; JANUS KINASE 3; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; SMAD2 PROTEIN; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR; STAT5 TRANSCRIPTION FACTOR; TH1 CELLS; TH17 CELLS; TH2 CELLS;

MURINAE; MUS;

EID: 84856628204     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.12.156     Document Type: Article

References (19)

1. Tamiya T., Kashiwagi I., Takahashi R., et al. Suppressors of cytokine signaling (SOCS) proteins and JAK/STAT pathways: regulation of T-Cell Inflammation by SOCS1 and SOCS3. Arterioscler. Thromb. Vasc. Biol. 2011, 31:980-985.
2. Changelian P.S., Flanagan M.E., Ball D.J., et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. SCIENCE 2003, 302:875-878.
3. Williams N.K., Bamert R.S., Patel O., et al. Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains. J. Mol. Biol. 2009, 387:219-232.
4. Coombs J.H., Bloom B.J., Breedveld F.C., et al. Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial. Ann. Rheum. Dis. 2010, 69:413-416.
5. Mori T., Miyamoto T., Yoshida H., et al. IL-1 and TNF -initiated IL-6-STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis. Int. Immunol. 2011, 23:701-712.
6. Thompson J.E., Cubbon R.M., Cummings R.T., et al. Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor. Bioorg. Med. Chem. Lett. 2002, 12:1219-1223.
7. Nakagawa R., Yoshida H., Asakawa M., et al. Pyridone 6, a pan-JAK inhibitor, ameliorates allergic skin inflammation of NC/Nga mice via suppression of Th2 and enhancement of Th17. J. Immunol. 2011, 187:4611-4620.
8. Matsunaga Y., Inoue H., Fukuyama S., et al. Effects of a Janus kinase inhibitor, pyridone 6, on airway responses in a murine model of asthma. Biochem. Biophys. Res. Commun. 2011, 404:261-267.
9. Ichiyama K., Sekiya T., Inoue N., et al. Transcription factor Smad-independent T helper 17 cell induction by transforming-growth factor-& beta is mediated by suppression of eomesodermin. Immunity 2011, 34:741-754.
10. Tanaka K., Ichiyama K., Hashimoto M., et al. Loss of suppressor of cytokine signaling 1 in helper T cells leads to defective Th17 differentiation by enhancing antagonistic effects of IFN-gamma on STAT3 and Smads. J. Immunol. 2008, 180:3746-3756.
11. Endo T.A., Masuhara M., Yokouchi M., et al. A new protein containing an SH2 domain that inhibits JAK kinases. Nature 1997, 387:921-924.
12. Hamanaka I., Saito Y., Yasukawa H., et al. Induction of JAB/SOCS-1/SSI-1 and CIS3/SOCS-3/SSI-3 Is Involved in gp130 resistance in cardiovascular system in rat treated with cardiotrophin-1 In Vivo. Circ. Res. 2001, 88:727-732.
13. Matsumura Y., Kobayashi T., Ichiyama K., et al. Selective expansion of foxp3-positive regulatory T cells and immunosuppression by suppressors of cytokine signaling 3-deficient dendritic cells. J. Immunol. 2007, 179:2170-2179.
14. Shiraishi H., Yoshida H., Saeki K., et al. Prostaglandin E2 is a major soluble factor produced by stromal cells for preventing inflammatory cytokine production from dendritic cells. Int. Immunol. 2008, 20:1219-1229.
15. Sanada T., Takaesu G., Mashima R., et al. FLN29 deficiency reveals its negative regulatory role in the toll-like receptor (TLR) and retinoic acid-inducible gene I (RIG-I)-like helicase signaling pathway. J. Biol. Chem. 2008, 283:33858-33864.
16. Ghoreschi K., Jesson M.I., Li X., et al. Modulation of innate and adaptive immune responses by tofacitinib. J. Immunol. 2011, 186:4234-4243.
17. Rodig S.J., Meraz M.A., White J.M., et al. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell 1998, 93:373-383.
18. Huh J.R., Leung M.W.L., Huang P., et al. Digoxin and its derivatives suppress TH17 cell differentiation by antagonizing RORγt activity. Nature 2011, 472:486-490.
19. Sundrud M.S., Koralov S.B., Feuerer M., et al. Halofuginone inhibits TH17 cell differentiation by activating the amino acid starvation response. SCIENCE 2009, 324:1334-1338.